(PharmaNewsWire.Com, August 10, 2017 ) In-vitro diagnostics (IVD) are used to detect diseases, infections, and conditions and also monitor a person's state of health and therapeutic procedures by examining specimens derived from the human body such as tissue, blood, stools, urine and the other body fluids. Significant technologies incorporated in in-vitro diagnostics are polymerase chain reaction, microarray techniques, sequencing technology and mass spectrometry, which are used for test sample preparation. In-vitro diagnostic medical devices include reagents, reagent products, control materials, calibration materials, kits, instruments, apparatus, systems, equipment, pregnancy tests, urine test strips, blood sugar monitoring systems for diabetics and receptacles for medical specimens.
Americas was the largest region in the In-Vitro Diagnostics market in 2016, accounting for over 45% of the market share. Asia was the second largest region accounting for over 22% of the market share. Europe was the third largest region accounting for over 20% of the market share.
Companies in this market are very active with multiple strategic collaborations and agreements. Top companies in the in-vitro diagnostic market are strategically partnering and collaborating with other companies to broaden their products, technologies and services. For instance, In February 2015, Roche acquired Signature Diagnostics to strengthen its cancer diagnostics effort with Signature's expertise in both next-generation sequencing (NGS) assays and biobanks. In February 2014, Thermo Fisher Scientific acquired the Life Technologies Corporation to transform into a major player in the segment of next-generation sequencing space
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Biotechnology & Pharmaceuticals resource center today to browse our selection of 600+ complimentary Biotechnology & Pharmaceuticals magazines, white papers, webinars, podcasts, and more. Get popular titles including:
